ADMA Biologics, Inc.
ADMA
$9.37
-$0.18-1.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 124.40M | 114.49M | 139.16M | 134.22M | 121.98M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 124.40M | 114.49M | 139.16M | 134.22M | 121.98M |
| Cost of Revenue | 38.12M | 33.74M | 50.35M | 58.60M | 54.76M |
| Gross Profit | 86.28M | 80.75M | 88.82M | 75.63M | 67.23M |
| SG&A Expenses | 27.76M | 27.80M | 24.64M | 23.05M | 23.37M |
| Depreciation & Amortization | 55.00K | 55.00K | 51.00K | 38.00K | 32.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.95M | 64.20M | 76.41M | 83.21M | 79.19M |
| Operating Income | 52.45M | 50.29M | 62.75M | 51.01M | 42.80M |
| Income Before Tax | 50.24M | 57.13M | 61.60M | 47.52M | 40.10M |
| Income Tax Expenses | 12.42M | 11.80M | 12.22M | 11.09M | 5.88M |
| Earnings from Continuing Operations | 37.82M | 45.33M | 49.38M | 36.43M | 34.22M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.82M | 45.33M | 49.38M | 36.43M | 34.22M |
| EBIT | 52.45M | 50.29M | 62.75M | 51.01M | 42.80M |
| EBITDA | 54.23M | 52.13M | 64.80M | 53.04M | 44.86M |
| EPS Basic | 0.17 | 0.19 | 0.21 | 0.15 | 0.14 |
| Normalized Basic EPS | 0.14 | 0.13 | 0.16 | 0.13 | 0.11 |
| EPS Diluted | 0.16 | 0.19 | 0.20 | 0.15 | 0.14 |
| Normalized Diluted EPS | 0.14 | 0.13 | 0.16 | 0.13 | 0.10 |
| Average Basic Shares Outstanding | 228.23M | 236.07M | 237.97M | 238.60M | 241.49M |
| Average Diluted Shares Outstanding | 230.34M | 239.96M | 243.85M | 244.66M | 248.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |